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Introduction
Sudden infant death syndrome (SIDS) is the sudden unexpected death of an infant less than 1 year of age, which remains unexplained despite comprehensive clinical and pathological investigations (1) . SIDS represents 70-80% of all sudden unexpected infant deaths with an incidence of 0.4/1000 live births in the UK and 0.5/1000 live births in the USA.(2,3) The peak incidence occurs between 2 -4 months of age and is more common in males. Such infant deaths are associated commonly with environmental risk factors such as co-sleeping or prone sleeping position.(4) Despite successful targeted risk reduction campaigns, the number of SIDS cases have plateaued, and SIDS remains the leading cause of post-neonatal mortality (4) .
A triple-risk model for SIDS suggest the convergence of the vulnerable infant in the setting of exogenous stressors during a critical development period (5) . Although many pathophysiologic theories have been proposed, decisive pathogenic substrates/mechanisms triggering an infant's sudden demise remain unclear (6) (7) (8) (9) . Several studies have implicated both common and rare genetic variants involved in autonomic function, neurotransmission, energy metabolism, response to infection, and cardiac repolarization (10) (11) (12) (13) (14) . Also, potentially lethal genetic heart diseases (GHDs) including long QT syndrome (LQTS), Brugada syndrome (BrS), catecholaminergic polymorphic ventricular tachycardia (CPVT), and hypertrophic cardiomyopathy (HCM) have been implicated as monogenic causes for a small proportion of SIDS cases (10, 13, (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) ).
However, less than 100 investigations of genetic variation in population-based SIDS cohorts have been published to date, largely based on hypothesis-driven, candidate gene/pathway-based approaches that recognize established pathobiological risk factors for SIDS, with an average cohort size of just 125 SIDS cases (13) . Here, using whole exome sequencing (WES), we conducted a GHD-associated gene-specific analysis on a cohort of over 400 unrelated SIDS cases.
Methods

Study Population
The SIDS cohort (N=427) consisted of 95 coroners' cases from the United Kingdom (UK; London, Sheffield, Edinburgh and Bristol) and 332 coroner/medical examiner/forensic pathologist-referred cases collected from six ethnically and geographically diverse United States (US) populations. Because of the lack of uniformity in procedures and reporting between medical examiner offices in the US, minor differences in protocols may exist. Nonetheless, both gross and histological examinations of all major organs were performed and all cases satisfied our enrolment criteria that included 1) sudden unexplained death of an infant < 1 year of age, 2)
European descent, and 3) a comprehensive negative medico-legal autopsy including a negative toxicology screen and death scene investigation. Infants with asphyxia or specific disease causing death were excluded. Ethnicity was self-reported by the referring coroner/medical examiner. This anonymous necropsy study only had limited medical information such as the sex, ethnicity age at the time of death, and sleep position available. This study complies with the Declaration of Helsinki; locally appointed ethics committees including Mayo Clinic's Institutional Review Board have approved the research protocol. Some of the 332 samples from the US have been included in previous publications that involved hypothesis-driven, specific candidate gene mutational analysis (10, 18, 19, (23) (24) (25) (26) (27) (28) . Of the 332 cases, 58 had been analyzed previously for variants in SCN5A (10) , KCNQ1 (18), KCNH2 (18), RYR2 (19), SNTA1 (23) , KCNJ8 (24) , Cx43 (25) , GPD1L (26) , CAV3 (27) , SCN1B (28) , SCN2B (28) , SCN3B (28) , and SCN4B (28) . An additional 25 of the 332 were also analyzed for RYR2 (19) and an additional 145 of the 332 cases were also analyzed for SNTA1 (23) , KCNJ8 (24) , Cx43 (25) , GPD1L (26), CAV3 (27) , SCN1B (28) , SCN2B (28) , SCN3B (28) , and SCN4B (28) . None of the 95 cases from the UK have been published previously.
Control Population
973 control exomes (509 females, 464 males) from the ICR1000 UK exome series and the 1958 Birth Cohort study were included for case-control analysis. (29) As previously reported, exome sequencing was performed using the Illumina TruSeq and Illumina instruments. (29) .
Whole Exome Sequencing (WES)
Genomic DNA isolated from each SIDS case underwent WES at the KCL-GSTT Biomedical Research Centre Genomics Platform, London, UK or Mayo Clinic's Medical Genome Facility, Rochester, Minnesota.
Paired-end libraries were prepared following the manufacturer's protocol (Agilent) using the Bravo liquid handler from Agilent. Briefly, 1-3 ug of genomic DNA was fragmented to 150-200 bp using the Covaris E210 sonicator. The ends were repaired and an "A" base was added to the 3' ends. Paired end Index DNA adaptors (Agilent) with a single "T" base overhang at the 3' end were ligated and the resulting constructs were purified using AMPure SPRI beads (Agencourt). The adapter-modified DNA fragments were enriched by 4 cycles of PCR using SureSelect forward and SureSelect ILM Pre-Capture Indexing reverse (Agilent) primers. The concentration and size distribution of the libraries was determined on an Agilent Bioanalyzer DNA 1000 chip.
Whole exon capture was performed using the protocol for Agilent's Sure SelectXT Human All Exon V5+UTR kit. Briefly, 750 ng of the prepped library was incubated with whole exon biotinylated RNA capture baits supplied in the kit for 24 hours at 65 °C. The captured DNA:RNA hybrids were recovered using Dynabeads MyOne Streptavidin T1 (Dynal). The DNA was eluted from the beads and purified using Ampure XP beads (Agencourt). The purified capture products were then amplified using the SureSelect Post-Capture Indexing forward and Index PCR reverse primers (Agilent) for 12 cycles.
Libraries were pooled at equimolar concentrations and loaded onto paired end flow cells at concentrations of 7-8 pM to generate cluster densities of 600,000-800,000/mm 2 following
Illumina's standard protocol using the Illumina cBot and HiSeq Paired end cluster kit version 3.
Each lane of a HiSeq flow cell produced 21-39 Gbases of sequence. The level of sample pooling was controlled by the size of the capture region and the desired depth of coverage.
The flow cells were sequenced as 101 X 2 paired end reads on an Illumina HiSeq 2000
using TruSeq SBS sequencing kit version 3 and HiSeq data collection version 2.0.12.0 software.
Base-calling was performed using Illumina's RTA version 1.17.21.3.
The FASTQ files underwent quality control checks using FASTQC. The Illumina paired end reads were aligned to the GRCh37 (hg19) human reference genome using Novoalign (http://novocraft.com). Single-sample variant calling with the Genome Analysis Toolkit (GATK, Version 3.2-2)(30) and the resulting gVCFs subsequently underwent multi-sample genotyping and variant quality score recalibration. Genotypes were excluded if the QC was < 15 or there were fewer than 4 reads supporting the call. Further filtering of variant sites was performed to exclude sites with missingness > 0.1 in cases or controls. Variants were annotated with respect to the genes in which they reside with Annovar, allele frequencies were obtained from the Exome Aggregation Consortium (ExAC) database and combined annotation dependent depletion (CADD) scores from the CADD server (http://cadd.gs.washington.edu).
Quality Control Coverage Analysis and Principal Component Analysis (PCA) for Relatedness and Ethnicity
Coverage across the exome was assessed using the Bedtools package cases were excluded from further analysis if < 75% of the Gencode defined protein coding exome was covered by < 20 reads. A set of 3847 common variants located outside of regions of the genome where there is extensive linkage disequilibrium were used to estimate relatedness within the study cohort and ethnic ancestry alongside the control group.(31) Estimation was undertaken using the first two dimensions of a Multidimensional Scaling (MDS) using Euclidean distance undertaken with the King software package.
Ancestry Confirmation
To avoid potential confounding due to population stratification resulting from genetic admixture, a principal component analysis (PCA) was performed (Online Supplement). The PCA served only for the rare variant analysis between European SIDS cases and European controls. The PCA data was not used for attributing causality to identified variants where ethnic matched controls would not be necessary for variant adjudication. SIDS cases and controls forming a homogeneous cluster on the first two components were included in the case-control rare variant analysis.
Genetic Heart Disease (GHD)-Gene Specific Variant Analysis
Known cardiac channelopathy-(LQTS, CPVT, BrS) and cardiomyopathy-(HCM, DCM, ACM) susceptibility genes (N=90, Online 
Results
Demographics
WES was performed in 427 SIDS cases. However, quality control metrics excluded 7 cases due to insufficient exome coverage and one individual from a half-sibling pair (Online Figure 1) . The cohort therefore consisted of 419 cases (257 males, 162 females; average age = 2.7 ± 1.9 months) with a skewed bell-shaped distribution of age (Online Figure 2) Figure 3 , Table 1 ). Sleep characteristics were known in 54% of the cohort ( Table 1 ). There were no significant differences in demographics and sleep characteristics between the European and mixed-European ancestry cases.
Genetic Heart Disease (GHD) Gene-Specific Analysis
Overall, a total of 285 unique, ultra-rare NSVs There were no significant differences in the yield of either ultra-rare NSVs among all 90
GHD genes or "potentially informative" variants when comparing gender, sleep position (supine vs prone), or co-sleeping (yes vs no) in either the overall or stratified populations (Table 3) .
However, there was a significantly higher yield of "potentially informative" GHD-associated genetic variants in those infants that died at greater than 4 months of age (15/65, 23.1%) compared to those younger than 4 months of age (37/354, 10.4%, p=0.0075, Figure 2 ).
Following further vetting using the strict ACMG guidelines, only 17 of the 285 ultra-rare NSVs achieved a "pathogenic" or "likely pathogenic" designation and were identified in 17 
Case-Control Analysis
Consistent with previous studies, there was a significant over-representation of ultra-rare Figure 3 ). However, there was no significant difference in yield between cases and controls for any specific gene.
Discussion
This manuscript reports results derived from a whole exome molecular autopsy with GHD gene-specific analysis of the largest cohort of unrelated SIDS cases. Previous post-mortem genetic studies have implicated pathogenic mutations in cardiac channelopathy-associated genes as a monogenic cause for up to 15% of SIDS (13, (16) (17) (18) (19) 23 ). Furthermore, rare HCM-associated sarcomere gene variants were implicated recently in 3.5% of SIDS (21). However, based on their prevalence in gnomAD, only 1.4% of these SIDS cases hosted variants rare enough to be considered pathogenic.
Because of the rarity of SIDS and any likely causative disorders, we used a strict minor allele frequency cut-off equivalent to a heterozygous frequency of less than 1 in 10,000 individuals in gnomAD. Despite using this very conservative rarity filter, 46% of our SIDS cohort harbored novel or ultra-rare, protein-altering genetic variants within 68 of the 90 GHDsusceptibility genes. Unfortunately, despite their rarity, the vast majority of these ultra-rare variants still remain variants of uncertain significance (VUS) stuck in genetic purgatory.(34,35)
In fact, about 25% of these 90 GHD-associated genes have a negative Z-score suggesting they tolerate variation (32,36).
Due to ambiguity surrounding the pathogenic nature of many GHD genes that play a "minor" role in their respective diseases, we examined the yield of ultra-rare NSVs with the highest likelihood of being true pathogenic mutations. Overall, about 13% of our SIDS cases hosted "potentially informative" variants regarded as having the greatest probability of being causative for the infant's sudden death and having potential clinical utility for assessing a family for genetic risk. Unfortunately, the anonymous nature of the cohort prevents us from verifying their presence among family members for the purpose of potential genotype-phenotype cosegregation analysis or to determine the frequency of de novo status of the variants of interest.
Importantly, not all of these variants have been characterized functionally and great caution must still be exercised, even when interpreting ultra-rare variants residing within the major channelopathy genes.
Recently, Hertz reported a 34% yield of "variants with likely functional effects"
following a genetic analysis of GHD-associated genes in only 47 sudden unexpected deaths in Tragically, this became a reality for one family described by Ackerman and colleagues recently, as they dealt with the disastrous consequences of unnecessary treatment based on an erroneously interpreted variant in KCNQ1 (35). Thus, over attribution of SIDS deaths to GHDs has significant implications for the immediate family and we urge extreme caution in variant interpretation. When such cautionary advice is heeded, less than 5% of over 400 SIDS cases had either a "pathogenic" or "likely pathogenic" variant in one of 90 GHD-susceptibility genes which is substantially lower than previous extrapolations of the prevalence of either channelopathic-or cardiomyopathic-SID. This parallels our experience of the 'molecular autopsy' in unexplained sudden death where stringent variant evaluation results in a significant reduction of numbers of 'likely pathogenic' and 'pathogenic' variants of clinical utility (38).
Using a similarly stringent variant analysis, we observed previously a 13% (40/302) yield of ultra-rare "pathogenic" or "likely pathogenic" variants within sudden death-susceptibility genes among 302 autopsy-negative sudden arrhythmic death syndrome (SADS) cases that died at an age greater than 1 year (median age 24 years), compared with a significantly (p=0.00002) lower yield of 4.3% (18/419) in our SIDS cohort (38). This data suggests that the majority of SIDS stems from pathobiological bases that are largely different genetically and mechanistically from sudden death occurring after the age of 1 year.
Several risk factors for SIDS have been established. One might hypothesize that vulnerable infants dying of SIDS without the presence of additional risk factors are more likely to host a highly penetrant monogenic cause for their death compared to infants exposed to additional environmental risk factors. Yet, no significant differences in the yield of "potentially informative" GHD gene variants associated with sex, sleep position, or bed sharing were observed. However, a significant age-effect on the yield, where 23% of those infants older than 4 months of age hosted a "potentially informative" GHD-associated variant compared to only 10% of the infants younger than 4 months of age was observed. This data supports potential stratification of those SIDS cases that may benefit most from post-mortem genetic testing of the major channelopathy/cardiomyopathy-associated genes.
The significant over-representation of ultra-rare NSVs within the 4 major channelopathy genes associated with either inheritable LQTS (KCNQ1, KCNH2, SCN5A) or CPVT (RYR2) observed in our European Caucasian SIDS compared to ethnic matched controls (6.5% vs 3.1%, p=0.013) supports that cardiac channelopathies may represent the underlying pathogenic basis for some of SIDS and that post-mortem genetic testing of the 4 major channelopathy associated genes may be warranted in cases of SIDS.
In our study, we used a strict MAF cut-off 0.005% (i.e. 1 in 20,000 alleles or 1 in 10,000 individuals). While using a stringent threshold could reduce the possibility of identifying variants that would be deemed too common in the population to cause a rare disease such as LQTS, it could also prevent the identification of potentially important functionally significant 
Conclusions
A whole exome molecular autopsy followed by a cardiac gene specific focus reveals that less than 15% of over 400 SIDS cases had a "potentially informative" variant in one of 90 GHDsusceptibility genes. Furthermore, less than 5% of these infant deaths possessed variants that are immediately useful in a family for further cascade testing. This represents a substantial reduction of the perceived importance of monogenic cardiac genetic disease in SIDS compared to previous studies. Interpretation of GHD-associated rare variants must therefore be stringent and careful
given the implications of misattribution in families. This has important clinical implications for the community managing SIDS cases and their relatives.
Perspectives
Competency in Medical Knowledge: Post-mortem genetic testing using whole exome sequencing (aka, the whole exome molecular autopsy or WEMA) may identify ultra-rare nonsynonymous variants within genetic heart disease-susceptibility genes that may underlie the pathogenic basis for a significant number of sudden infant death syndrome (SIDS) cases, predominantly in the 4-12 month age group. However, the yield of ultra-rare non-synonymous variants in all but the 'major' channelopathy genes is very similar in a healthy population, suggesting that single gene cardiac disorders are not the major cause of SIDS. In fact, less than 15% of SIDS cases possessed a 'potentially informative' variant regarded as having the greatest probability of being causative for the infant's sudden death and having potential clinical utility for assessing the potential risk in family members left behind. Furthermore, clinically relevant variants that are immediately useful in a family for cascade/predictive testing were identified in only 4% of infant deaths.
Translational Outlook 1:
While some of the ultra-rare 'potentially informative' variants may be disease-causing and contributing to SIDS pathogenesis, future research involving functional studies are necessary to determine which variants are truly pathogenic and whether cardiac genetic disease is a more significant contributor than our data currently suggest. variants, and ACMG guideline-specified "pathogenic" or "likely pathogenic" variants that were identified among the 90 genetic heart disease (GHD)-associated genes for the overall, European
Caucasian, and Mixed-European Ancestry cohorts. 
